NSCLC Flashcards
NSCLC accounts for ___% of all new lung cancer diagnoses.
80%
What is the gold standard of mediastinal lymph node evaluation?
Mediastinoscopy
___% of patients diagnosed with NSCLC are eligible for resection.
35%
What is the five year survival of a complete resection if stage I disease?
70%. 80% of these patients never have a recurrence. 15-20% die within five years from causes unrelated to their NSCLC.
What is the five year survival of a complete resection if stage IIa disease?
About 55%.
What is the five year survival of a complete resection if stage IIB disease?
40%
What is the five year survival of a complete resection if stage IIIA disease?
25-39%
What is the five year survival of a complete resection if stage IIIB disease?
About 6%
What is the five year survival of a complete resection if stage IV disease?
1-7%. Rami-Porta did report a survival of 25%, but the number of patients was low (n=27). A much larger series by Mountain (n=1427) had only a 1% survival.
How often does PET prevent no therapeutic thoracotomy?
6.3%
What is the positive predictive value of PET for mediastinal lymph node disease?
56%
Is mediastinoscopy necessary for IA disease?
No. The overwhelming majority will not have N2 disease.
What percentage of T2-4 patients with a negative mediastinum in CT/PET have occult nodal metastasis?
15%.
How does lobectomy compare to lesser resections (wedge or segmentectomy) for stage I disease in the Lung Cancer Study Group?
Local recurrence better in lobectomy (6.4 vs 17.2%). Overall survival also better with lobectomy. Long term survival was reduced by 30% in the group receiving lesser resections.
How does 5Y survival of sleeve lobectomy compare to pneumonectomy.
Sleeve 52% vs pneumonectomy 31%
How does operative mortality of sleeve lobectomy compare to pneumonectomy.
Sleeve 1.6% vs pneumonectomy 5.3%
Operative mortality of completion pneumonectomy?
21%
Keenan and colleagues reported 4 year survival of anatomic segmentectomy vs lobectomy?
67 vs 62%. The text doesn’t say whether they were randomized or not.
How does wedge resection generally compare to lobectomy?
Higher rate of local recurrence despite negative margins and a trend toward reduced survival.
What are contraindications to VATS Lobectomy?
Inability to tolerate one lung ventilation, large tumor >4cm, a fused pleural space, established N2 disease.
Is there a difference in LN met detection in LN sampling vs dissection?
ECOG group: They are equivalent for detecting N1 and N2 disease, but dissection detected more levels of N2 disease and suggested a survival advantage for stages II and IIIA NSCLC.
This was corroborated by a Chinese study demonstrating median survival of complete dissection being 59 months vs 34 months in the nodal sampling group (P<.05).
What % of patients without metastatic disease in CT are found to have metastatic disease on PET?
6%
How often does PET give a false positive?
6.6%
How does the sensitivity of PET compare to CT in detection of lymph node metastasis?
42 v 13% (P=.02)
What is the negative predictive value of PET for mediastinal node disease?
87%
Should stage IB or II receive chemotherapy after complete resection?
Yes. There is a significant improvement in recurrence free and overall survival. This effect seems to be true for rumors 4cm or greater. The 15% improvement in survival is more than that observed for many other cancers for which adjuvant chemotherapy has become routine.
After completely respected stage I disease, how many develop a recurrence?
20-30%
After completely respected stage I disease, how many develop a solitary brain met?
20%
What percentage of stage II patients require pneumonectomy for complete resection?
30% Memorial Sloan Kettering series of 214 patients.
Is there a role for adjuvant radiation in R0 Stage II resection?
Yes, radiation decreases risk local and regional recurrence, but there is no impact on survival.
Is there a role for adjuvant chemotherapy in R0 Stage II resection?
Yes. Medically fit patients should receive adjuvant chemotherapy. A prospective randomized trial in patients with stage II completely resected non-small cell lung cancer have a large survival advantage when treated with postoperative vinorelbine plus cisplatin.
The median survival time was 41 months in the observation group and 80 months in the chemotherapy group (P=.004). NEJM 352:2589, 2005.
Difference in 5 year survival between single or multiple positive lymph nodes in stage two disease?
Single: 45%
Multiple: 31%
JTCS 109:120, 1995
T1
3 cm or less
T1a
2 cm for less